---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-106664"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:13:14.065057+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q3 net loss $20M; OCU400 Phase 3 nearing completion, Kwangdong deal signed

## Summary
- Net loss of $20.0M ($0.07/sh) vs $13.0M ($0.05) in Q3 2024; cash $32.9M as of Sep 30 (down from $58.8M Dec 31).
- OCU400 Phase 3 enrollment nearing completion; BLA filing target 1H 2026, top-line data expected 4Q 2026.
- OCU410ST Phase 2/3 trial 50% enrolled; CHMP accepts single US trial for MAA; interim data mid-2026.
- Signed licensing deal with Kwangdong for OCU400 in South Korea; up to $7.5M milestones plus sales milestones and 25% royalties.
- Closed $20M registered direct offering; cash runway into Q2 2026; warrants exercise could add $30M and extend to 2027.

## SEC filing metadata
- accession: 0001104659-25-106664
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/0001104659-25-106664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-106664
- JSON: https://secwatch.observer/filing/0001104659-25-106664.json
- Plain text: https://secwatch.observer/filing/0001104659-25-106664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.